Hepatotoxicity from antithyroid drugs

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

TCTR

Registry ID

TCTR20180128001

Enrollment

Unknown

Registered

2018-01-28

Start date

2016-07-05

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperthyroidism treated with antithyroid drugs Hepatotoxicity&#44

Interventions

Cases were patients who developed hepatotoxicity from ATD. ,Controls were patients without hepatotoxicity after using ATD.The ratio of case : control was 1:4 and non&#45

match groups.

Treatment,Treatment

Cases,Controls

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age more than 18 years old 2. Hyperthyroidism patient who treat with MMI or PTU

Exclusion criteria

Exclusion criteria: 1. Abnormal liver function before treating hyperthyroidism 2. Abnormal liver function from other causes example viral hepatitis, ischemic hepatitis, autoimmune hepatitis

Design outcomes

Primary

Measure	Time frame
Risk of hepatotoxicity from antithyroid drugs During treatment with antithyroid drugs Abnormal LFT during antithyroid drugs treatment	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactTada Kunavisarut

Mahidol University

kunavisarut@gmail.com0843878300

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026